CY2006002I1 - Αυτογαλακτωματοποιος σχηματισμος για οξυφορες λιποφυλικες ενωσεις - Google Patents

Αυτογαλακτωματοποιος σχηματισμος για οξυφορες λιποφυλικες ενωσεις

Info

Publication number
CY2006002I1
CY2006002I1 CY2006002C CY2006002C CY2006002I1 CY 2006002 I1 CY2006002 I1 CY 2006002I1 CY 2006002 C CY2006002 C CY 2006002C CY 2006002 C CY2006002 C CY 2006002C CY 2006002 I1 CY2006002 I1 CY 2006002I1
Authority
CY
Cyprus
Prior art keywords
self
lipophilic compounds
emulsifying formulation
acid lipophilic
acid
Prior art date
Application number
CY2006002C
Other languages
English (en)
Other versions
CY2006002I2 (el
Original Assignee
Pharmacia & Upjohn Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Company filed Critical Pharmacia & Upjohn Company
Publication of CY2006002I1 publication Critical patent/CY2006002I1/el
Publication of CY2006002I2 publication Critical patent/CY2006002I2/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
CY2006002C 1997-07-29 2006-02-28 Αυτογαλακτωματοποιος σχηματισμος για οξυφορες λιποφυλικες ενωσεις CY2006002I2 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5401297P 1997-07-29 1997-07-29
PCT/US1998/014817 WO1999006044A1 (en) 1997-07-29 1998-07-27 Pharmaceutical composition for acidic lipophilic compounds in a form of a self-emulsifying formulation

Publications (2)

Publication Number Publication Date
CY2006002I1 true CY2006002I1 (el) 2011-02-02
CY2006002I2 CY2006002I2 (el) 2012-01-25

Family

ID=21988155

Family Applications (1)

Application Number Title Priority Date Filing Date
CY2006002C CY2006002I2 (el) 1997-07-29 2006-02-28 Αυτογαλακτωματοποιος σχηματισμος για οξυφορες λιποφυλικες ενωσεις

Country Status (25)

Country Link
US (1) US6231887B1 (el)
EP (1) EP0989851B1 (el)
JP (1) JP4524367B2 (el)
KR (1) KR100509131B1 (el)
CN (1) CN1112927C (el)
AT (1) ATE225174T1 (el)
AU (1) AU728626B2 (el)
BR (1) BR9810729B1 (el)
CA (1) CA2294033C (el)
CY (1) CY2006002I2 (el)
CZ (1) CZ296957B6 (el)
DE (1) DE69808463T2 (el)
DK (1) DK0989851T3 (el)
ES (1) ES2184310T3 (el)
FI (1) FI20000172A (el)
HK (1) HK1028879A1 (el)
HU (1) HU228923B1 (el)
NO (1) NO323425B1 (el)
NZ (1) NZ502566A (el)
PL (1) PL192865B1 (el)
PT (1) PT989851E (el)
RU (1) RU2202346C2 (el)
SI (1) SI0989851T1 (el)
SK (1) SK284616B6 (el)
WO (1) WO1999006044A1 (el)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
EP1165091B1 (en) * 1999-03-31 2005-01-26 PHARMACIA & UPJOHN COMPANY Pharmaceutical emulsions for retroviral protease inhibitors
US6956048B2 (en) 1999-03-31 2005-10-18 Pharmacia & Upjohn Company Pharmaceutical emulsions for retroviral protease inhibitors
SE0000773D0 (sv) * 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
SE0000774D0 (sv) * 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
MXPA03003795A (es) 2000-10-31 2003-08-20 Boehringer Ingelheim Pharma Formulaciones autoemulsionantes de dosis orales de inhibidores de proteasa de tipo piranona.
SE0102993D0 (sv) * 2001-09-07 2001-09-07 Astrazeneca Ab New self emulsifying drug delivery system
US20030165545A1 (en) * 2002-01-30 2003-09-04 Allergan, Inc. Ophthalmic compositions including oil-in-water emulsions, and methods for making and using same
JP2005523262A (ja) * 2002-02-01 2005-08-04 ファイザー・プロダクツ・インク 薬物及び親油性ミクロ相形成物質の非晶質分散物の医薬組成物
US6828301B2 (en) * 2002-02-07 2004-12-07 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for hepatitis C viral protease inhibitors
US20040191332A1 (en) * 2003-03-27 2004-09-30 Allergan, Inc. Preserved ophthalmic compositions
AU2004231538A1 (en) 2003-04-02 2004-11-04 Boehringer Ingelheim International, Gmbh Pharmaceutical compositions for hepatitis C viral protease inhibitors
BRPI0413277A (pt) 2003-08-04 2006-10-10 Pfizer Prod Inc composições farmacêuticas de adsorvatos de medicamentos amorfos e materiais que formam microfases lipofìlicas
EP1672985A1 (en) * 2003-10-07 2006-06-28 Eli Lilly And Company Liquid formulations of ractopamine
US20060122220A1 (en) * 2004-11-19 2006-06-08 Boehringer Ingelheim International Gmbh Method for treating HIV infection through co-administration of tipranavir and UK-427,857
US20060128733A1 (en) * 2004-11-19 2006-06-15 Boehringer Ingelheim International Gmbh Method for treating HIV infection through co-administration of tipranavir and reverset
EP1819348A1 (en) * 2004-12-01 2007-08-22 Boehringer Ingelheim International Gmbh Method for treating hiv infection through co-administration of tipranavir and gw695634
JP5028885B2 (ja) * 2006-07-04 2012-09-19 大正製薬株式会社 ユビデカレノン含有自己乳化組成物
EP2131865B1 (en) 2007-03-12 2014-12-17 Nektar Therapeutics Oligomer-protease inhibitor conjugates
EP2262538B1 (en) * 2008-03-12 2014-12-10 Nektar Therapeutics Oligomer-amino acid conjugate
US20120108501A1 (en) 2009-06-12 2012-05-03 Nektar Therapeutics Protease Inhibitors
DK2451438T3 (da) * 2009-07-07 2014-03-10 Boehringer Ingelheim Int Farmaceutisk sammensætning til en hepatitis C-virus-roteaseinhibitor
US9717703B2 (en) 2009-10-16 2017-08-01 Glaxosmithkline Llc Emulsion and emulsion preconcentrate compositions comprising omega-3 fatty acids and uses thereof are disclosed
RU2419426C1 (ru) * 2010-04-26 2011-05-27 Всеволод Иванович Киселев Лекарственное средство на основе дииндолилметана (dim) с повышенной биодоступностью и его использование в лечении гиперпластических и воспалительных заболеваний человека
ES2652509T3 (es) 2010-05-03 2018-02-02 Teikoku Pharma Usa, Inc. Formulaciones de proemulsión de taxano no acuosas y métodos para la preparación y el uso de las mismas
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
MX2015009045A (es) * 2013-01-14 2015-12-17 Infirst Healthcare Ltd Composiciones y metodos para tratar el dolor severo.

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4230702A (en) 1978-01-09 1980-10-28 Kali-Chemie Pharma Gmbh Readily enterally absorbable pharmaceutical compositions of per se poorly enterally absorbable pharmacologically active agents
DE3300793A1 (de) * 1983-01-12 1984-07-12 Bayer Ag, 5090 Leverkusen Coccidiosemittel
GB8903804D0 (en) * 1989-02-20 1989-04-05 Sandoz Ltd Improvements in or relating to organic compounds
US5071643A (en) 1986-10-17 1991-12-10 R. P. Scherer Corporation Solvent system enhancing the solubility of pharmaceuticals for encapsulation
GB2222770B (en) * 1988-09-16 1992-07-29 Sandoz Ltd Pharmaceutical compositions containing cyclosporins
GB9113872D0 (en) 1991-06-27 1991-08-14 Sandoz Ag Improvements in or relating to organic compounds
IL102236A0 (en) * 1991-06-27 1993-01-14 Ltt Inst Co Ltd Topical preparations containing cyclosporin
GB9208712D0 (en) * 1992-04-22 1992-06-10 Sandoz Ltd Pharmaceutical compositions containing cyclosporin derivates
US5376688A (en) 1992-12-18 1994-12-27 R. P. Scherer Corporation Enhanced solubility pharmaceutical solutions
IL129871A (en) * 1994-05-06 2003-11-23 Pharmacia & Upjohn Inc Process for preparing 4-phenyl-substituted octanoyl-oxazolidin-2-one intermediates that are useful for preparing pyran-2-ones useful for treating retroviral infections
EP0769936A1 (en) * 1994-07-22 1997-05-02 G.D. Searle & Co. Self-emulsifying drug delivery system
WO1996033697A1 (fr) * 1995-04-24 1996-10-31 Yissum Research Development Company Of The Hebrew University Of Jerusalem Formulation auto-emulsionnable formant une emulsion huile dans l'eau
CN1092960C (zh) 1995-06-06 2002-10-23 霍夫曼-拉罗奇有限公司 含蛋白酶抑制剂和单酸甘油酯的药物组合物
ZA9710071B (en) * 1996-11-21 1998-05-25 Abbott Lab Pharmaceutical composition.

Also Published As

Publication number Publication date
US6231887B1 (en) 2001-05-15
BR9810729B1 (pt) 2010-07-13
WO1999006044A1 (en) 1999-02-11
CN1261796A (zh) 2000-08-02
HK1028879A1 (en) 2001-03-09
CA2294033C (en) 2007-01-09
JP4524367B2 (ja) 2010-08-18
AU728626B2 (en) 2001-01-11
ES2184310T3 (es) 2003-04-01
SI0989851T1 (en) 2003-04-30
AU8573898A (en) 1999-02-22
NZ502566A (en) 2002-03-28
NO20000466D0 (no) 2000-01-28
PT989851E (pt) 2002-12-31
RU2202346C2 (ru) 2003-04-20
HUP0002440A3 (en) 2001-10-29
DE69808463T2 (de) 2003-06-26
CZ296957B6 (cs) 2006-08-16
HUP0002440A2 (hu) 2001-09-28
EP0989851A1 (en) 2000-04-05
BR9810729A (pt) 2000-08-08
DE69808463D1 (de) 2002-11-07
HU228923B1 (en) 2013-06-28
NO323425B1 (no) 2007-04-30
SK162000A3 (en) 2000-12-11
NO20000466L (no) 2000-03-28
SK284616B6 (sk) 2005-07-01
CN1112927C (zh) 2003-07-02
EP0989851B1 (en) 2002-10-02
CA2294033A1 (en) 1999-02-11
KR100509131B1 (ko) 2005-08-18
ATE225174T1 (de) 2002-10-15
JP2002510330A (ja) 2002-04-02
CY2006002I2 (el) 2012-01-25
PL192865B1 (pl) 2006-12-29
KR20010022369A (ko) 2001-03-15
DK0989851T3 (da) 2003-01-27
PL338335A1 (en) 2000-10-23
CZ2000156A3 (cs) 2000-05-17
FI20000172A (fi) 2000-01-28

Similar Documents

Publication Publication Date Title
CY2006002I2 (el) Αυτογαλακτωματοποιος σχηματισμος για οξυφορες λιποφυλικες ενωσεις
HUP0003292A3 (en) Self-emulsifying formulation for lipophilic compounds
HUP0002486A3 (en) Self-emulsifying formulation for lipophilic compounds
ID24654A (id) Formulasi farmasi omeprazola
NO20001631L (no) 2-metyl-tieno-benzodiazepin formulering
ATE248812T1 (de) Arylsulfonylhydroxamsäurederivate
DK1003720T3 (da) Aryloxyarylsulfonylaminohydroxamsyrederivater
PT860428E (pt) Compostos pirimidiona
IS5479A (is) Efnasambönd
IS5477A (is) Efnasambönd
ATE227933T1 (de) Glyphosat-formulierung
ID23299A (id) Formulasi-formulasi farmasi
DK1073417T3 (da) Farmaceutisk aerosolformulering
MA24473A1 (fr) Formulations
ID28698A (id) Formulasi antiparasit
DK1109449T3 (da) Mikrokapselformuleringer
ID20323A (id) Senyawa-senyawa triazinilaminostilbena
DK0975623T3 (da) Indazolamidforbindelser som sertoninerge midler
DE69935609D1 (de) Formulierungen enthaltend cefuroxim-axetil
ATE232683T1 (de) Mikrokapsel-formulierungen
DE69801941D1 (de) Kautschukzusammensetzungen welche o-Salicylsalicylicsäure enthalten
ID28810A (id) Senyawa-senyawa amida-omega asam n-arilsulfonilamino
NO991561D0 (no) 3-alkoksyisoksazol-4-yl-substituerte 2-aminokarboksylsyreforbindelser
DE69708130T2 (de) A-oxo-butansäuren enthaltende pharmazeutische zusammensetzung
ID30032A (id) Formulasi farmasi